Xavier Tillou (@XTillou) header
Xavier Tillou (@XTillou) profile picture

Full Professor of Urology. Head of Urology and Transplantation dpt. Transplant surgeon. PhD in immunology. FEBU #urology #transplant #Health #ehealth #education

CHU de Caen
Joined November 2014
Photo by Xavier Tillou (@XTillou)Photo by Xavier Tillou (@XTillou)Photo by Xavier Tillou (@XTillou)Photo by Xavier Tillou (@XTillou)Photo by Xavier Tillou (@XTillou)Photo by Xavier Tillou (@XTillou)Photo by Xavier Tillou (@XTillou)Photo by Xavier Tillou (@XTillou)Photo by Xavier Tillou (@XTillou)Photo by Xavier Tillou (@XTillou)
Dr Jay Raman @urojdr Hematuria Risk-based Evaluation & Indications for Markers #CAU25
1
3
1
16
1,170
🚨 New publication alert! 💊Enzalutamide before ☢️¹⁷⁷Lu-PSMA-617 improves OS vs. abiraterone in mCRPC. Stronger PSMA expression, better sequencing and survival! @OncJournal @OncoAlert @APCCC_Lugano @coskunyazgann @hatice_bolek @nahit_sendur @drdeniztural @yekeduz_emre doi.org/10.1093/oncolo/oyaf2…
5
33
3
117
8,021
15
37
1
286
15,804
Xavier Tillou retweeted
Qualitative researchers when they see statistics xitter.gq/HumansNoContext/status…
34
164
38
892
59,349
🚨TP vs TR prostate biopsy🚨 📜TRANSLATE RCT out in @TheLancetOncol 👉Transperineal biopsy... 1⃣More ≥GG2 #prostatecancer detected 2⃣Similar to possibly fewer infections WITHOUT any antibiotic prophylaxis 🔗shorturl.at/JG0J6 👏#EAU25 @LabBryant @LambAlastair @PCF_Science @PCFnews @urotoday @UrologyTimes @renalandurology @ZEROCancer
4
26
79
7,594
69
1,942
77
15,603
590,744
Xavier Tillou retweeted
5. Results from the first pig-to-living human kidney transplant To reduce the risk of rejection and to inactivate pig retroviruses, 69 edits to the pig's genome were made, with CRISPR There was a challenging course post-surgery in this case, but this approach could massively broaden the supply of kidneys available for transplant nejm.org/doi/full/10.1056/NE…
1
11
1
98
6,901
Xavier Tillou retweeted
Replying to @XTillou @OncoAlert
Advanced imaging techniques like PET PSMA are indeed revolutionizing how we classify and manage metastatic castration-sensitive prostate cancer (mCSPC). However, the challenge remains to translate these advancements into concrete therapeutic pathways. Clinical trials are essential to bridge this gap by assessing the impact on patient outcomes. Have there been any trials proposed, or is there a specific trial design you think would be beneficial? #Medicine #ProstateCancer. For a deeper dive into biomedical developments, check out sciqst.com. It's a one-stop platform for generating comprehensive reviews on all your biomedical questions. Support Medical Doctors in Uganda: Help by sharing this GoFundMe! 🙏 ❤️ → gofund.me/8be43dd7
1
1
61
Xavier Tillou retweeted
A warm invitation to JOIN US at #APCCCDiagnostics25 🇨🇭in Lugano A HYBRID Meeting (In Person & Live) Switzerland February 27-28, 2025 REGISTER: apccc.org/apccc-diagnostics-… ONLINE REGISTRATION FOR LMIC's FREE OncoAlert 🚨Will be Live in Lugano with Coverage🇨🇭 In recent years, diagnostic capabilities for Prostate #Cancer have significantly advanced through innovations in imaging, biomarkers, and the introduction of PSMA PET imaging, which have reshaped traditional diagnostic approaches. To address these advancements and their growing relevance in early detection, a new conference series, APCCC Diagnostics, will launch in February 2025 in Lugano, Switzerland, focusing on #ProstateCancer diagnostics. @APCCC_Lugano Scientific Committee @ProfKHerrmann 🇩🇪 @stefanofanti4 🇮🇹 @Silke_Gillessen 🇨🇭 @AOmlin 🇨🇭 Ambassadors @ZilliThomas 🇨🇭 @LoebStacy 🇺🇸 @nataliagandur 🇦🇷 @bavilima 🇧🇷 @fabioturco92 🇨🇭 @DrYukselUrun 🇹🇷 @weoncologists 🇺🇸
12
4
22
9,791
🌟 Neoadjuvant Therapy in High-Risk Localized Prostate Cancer: What’s New? 📖 Key Takeaways: High-risk localized prostate cancer has higher chances of recurrence and progression compared to low/intermediate risk. Androgen deprivation therapy (ADT) reduces tumor size but shows no survival benefit. Second-generation agents (like ARPIs) are showing promise in improving survival outcomes in trials. 💡 Highlights from the Review: 1️⃣ Guideline Status: Neoadjuvant therapy is not yet standard care, recommended only within clinical trials. 2️⃣ Promising Trials: Phase II studies suggest better pathological outcomes and lower relapse rates with ADT + ARPIs. 3️⃣ Future Directions: Innovative therapies like Lu-177 PSMA and genomics-based treatments hold potential for personalized care. 🧬 What’s Next?: More robust Phase III trials are needed to solidify these therapies as game-changers! 👩‍⚕️👨‍⚕️ For clinicians and researchers: The focus remains on improving biomarkers and identifying patients who will benefit most. 🔗 Read more: pubmed.ncbi.nlm.nih.gov/3979… #ProstateCancer #urology #oncology @JesusMorenosier @Galante_Isabel @ortegapolledo @Chusi132 @Dmitry_Enikeev @endouro @monterrubio93 @BeaGutih @docjavip @IIS_IdISSC @UrologiaClinico #somosclinico
3
37
2
95
10,227
🧵regarding errors that can be made when using the Bovie during surgery. This is the followup from my 🧵from last month, which went over some of the basics of the Bovie (link at the end). Here we will look at a few of the common mistakes that can be made using the Bovie. (1/ )
14
127
8
706
195,799
Xavier Tillou retweeted
🚨 PSMA-PET in Biochemically Recurrent Prostate Cancer: A Paradigm Shift❗️ ✔️Recent findings reveal that PSMA-PET/CT detects M1 metastatic disease in 46% of 👥 previously classified as non-metastatic by conventional imaging. This study sheds light on the limitations of traditional staging in high-risk, hormone-sensitive prostate cancer⚠️ 📊 Key Findings: •84% PSMA-PET ➕: Across 👥 w/ biochemical recurrence •46% detected M1 disease: A substantial rate of under-staged metastases •Polymetastatic disease (>5 lesions): Found in 24% of cases😱 🔍 Implications: Conventional imaging underestimates disease burden, potentially altering treatment plans. PSMA-PET offers ⬆️accuracy for staging and risk stratification, guiding interventions like MDT and systemic treatment
3
34
2
87
13,038
IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024 1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos ⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45) ⏩ OS benefit: 31.5 vs 16.1 mo (HR= 0.47) @tompowles1 @NEJM #ESMO2023 Plenary nejm.org/doi/full/10.1056/NE…
7
240
9
538
82,815
And NOW, TOP 5 PROSTATE CANCER trials of 2024! 1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%,--Benefits seen across all subgroups with a favorable safety profile. ⛹🏼‍♂️A new player for doublets in mHSPC! #ESMO24 Dr. Fred Saad @Silke_Gillessen @neerajaiims @umangtalking @DrRanaMcKay @JCO_ASCO doi.org/10.1200/JCO-24-01798
5
169
6
366
45,588
The journey of my paper 😭
3
19
74
8,627
110
3,552
92
22,851
717,230
Félicitations au nouveau bureau @denis_seguier @GaelleMargue @ArthurPeyrottes @S_Levy_Urologue de l @afufuro L @AFUrologie soutient et travaille avec la jeune génération pour sa formation, ses recherches et son implication dans ses comités scientifiques ! @futur/afu
L'@afufuro vous présente son nouveau conseil d'administration ! 🚀 Une nouvelle mandature débute aujourd'hui autour d'un bureau élargi avec @denis_seguier Président, @GaelleMargue Vice-présidente, @ArthurPeyrottes Secrétaire et @S_Levy_Urologue Trésorier. #CFU2024 @AFUrologie
2
3
14
1,034
#CFU2024 | Piqure de rappel : la maladie lithiasique urinaire presente ou passée n’est pas une contre-indication au don de rein @UhlMarine @Charlesgaill. En cas de doute sur l’éligibilite du donneur, les recommandations du CTAFU vous guident !
3
5
682
4
29
6,364
1
22
3
203
24,709